Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
IMT-009 by Immunitas Therapeutics for Follicular Lymphoma: Likelihood of Approval
IMT-009 is under clinical development by Immunitas Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Data Insights
IMT-009 by Immunitas Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
IMT-009 is under clinical development by Immunitas Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...